JPRN-UMIN000002165已完成未知
Cetuximab biomarker study - C-MAb BM study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.active synchronous malignancy 2.pregnancy 3.severe psychological disease 4.systemic steroid administration 5.HBV carrier 6.uncontrolled diabetes 7.severe fluid collection 8.bowel obstruction 9.cardiovasucular disease within 3months 10.severe comorbidity 11.active infection
研究者
相似试验
进行中（未招募）
不适用
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
招募中
1 期
Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapyunresectable metastatic colorectal cancerJPRN-UMIN000004579Department of medical oncology, Cancer institute hospital, in Japan41
进行中（未招募）
不适用
Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapyPatients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy.MedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-002811-98-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE100
已完成
不适用
Safety assessment of treatment with cetuximab in metastatic colorectal cancer patientsMetastatic colorectal cancerMalignant neoplasm of other and ill-defined digestive organsCancerISRCTN34968597Institute of Oncology Ljubljana (Slovenia)250
进行中（未招募）
不适用
A Stratified Phase II Study of Cetuximab (ErbituxTM) for the Treatment of Recurrent Glioblastoma Multiforme / Estudio de fase II estratificado de cetuximab para el tratamiento del glioblastoma multiforme recidivante - Cetuximab for recurrent GBMpatients with a recurrent glioblastoma multiforme following preceding surgery, radiation therapy and chemotherapyEUCTR2005-000459-14-ESOncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel54